Physiology and pathology of eosinophils: Recent developments: Summary of the Focus Workshop Organized by DGAKI.
Animals
Biomarkers
Cell Communication
/ genetics
Cytokines
/ metabolism
Disease Management
Disease Susceptibility
Eosinophilia
/ diagnosis
Eosinophils
/ physiology
Homeostasis
/ genetics
Host-Pathogen Interactions
/ immunology
Humans
Inflammation Mediators
/ metabolism
Leukocyte Count
Mast Cells
/ immunology
Organ Specificity
DNAzyme against GATA3; eosinophil
anti-interleukin 5
eosinophil diseases
hypereosinophilic syndrome
Journal
Scandinavian journal of immunology
ISSN: 1365-3083
Titre abrégé: Scand J Immunol
Pays: England
ID NLM: 0323767
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
revised:
10
02
2021
received:
03
09
2020
accepted:
21
02
2021
pubmed:
25
2
2021
medline:
2
6
2021
entrez:
24
2
2021
Statut:
ppublish
Résumé
Over the last century, eosinophils have been regarded ambiguously either as 'friends' or 'foes'. Recent developments have greatly enhanced our understanding of the role and function of eosinophils in health and disease. Pathogenic eosinophilic inflammation can lead to severe diseases in various organs, such as the gastrointestinal tract, airways, heart and skin. In a 2-day focus workshop of the German Society for Allergology and Clinical Immunology (DGAKI), the state of the art was discussed and practical recommendations for diagnosis and treatment of eosinophilic diseases, with a particular focus on new biologics, such as anti-interleukin 5 and anti-interleukin 5R, were derived.
Substances chimiques
Biomarkers
0
Cytokines
0
Inflammation Mediators
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13032Subventions
Organisme : Universities Giessen Marburg Lung Center
Organisme : German Center for Lung Disease
ID : 82DZL00502
Organisme : European Commission's Seventh Framework Program
ID : 260895
Organisme : Flemish Scientific Research Board
ID : 1841713N
Organisme : Flemish Scientific Research Board
ID : G.039412N
Organisme : Flemish Scientific Research Board
ID : G.067512N
Organisme : Flemish Scientific Research Board
ID : BOF14/GOA/019
Organisme : Interuniversity Attraction Poles Program of the Belgian State Science Policy Office
ID : IAP P7/30
Organisme : Interuniversity Attraction Poles Program of the Belgian State Science Policy Office
ID : SFB F47-B20
Organisme : Austrian Science Fund
Organisme : German Ministry of Education and Research
ID : 01GL1742D CHAMP
Organisme : DFG
ID : Vo944/9-1
Organisme : DFG
ID : RA 1026 3-1
Organisme : Christine Kuehne Center for Allergy Research and Education
Organisme : Hanover Medical University
Informations de copyright
© 2021 The Authors. Scandinavian Journal of Immunology published by John Wiley & Sons Ltd on behalf of The Scandinavian Foundation for Immunology.
Références
Ehrlich P. Beiträge zur Kenntnis der Anilinfärbungen und ihre Verwendung in der mikroskopischen Technik. Arch Mikroskop Anat. 1877;263-277.
Chusid MJE. Friends or Foes? The journal of allergy and clinical immunology. practice. 2018;6:1439-1444.
Berek C. Eosinophils can more than kill. J Exp Med. 2018;215:1967-1969.
Gleich GJ, Klion AD, Lee JJ, Weller PF. The consequences of not having eosinophils. Allergy. 2013;68:829-835.
van Chu T, Beller A, Rausch S, et al. Eosinophils promote generation and maintenance of immunoglobulin-A-expressing plasma cells and contribute to gut immune homeostasis. Immunity. 2014;40:582-593.
Wen T, Rothenberg ME. The Regulatory Function of Eosinophils. Microbiology spectr. 2016;4(5). https://doi.org/10.1128/microbiolspec.MCHD-0020-2015. (ahead of print).
Arnold IC, Artola-Borán M, Tallón de Lara P, et al. Eosinophils suppress Th1 responses and restrict bacterially induced gastrointestinal inflammation. J Exp Med. 2018;215:2055-2072.
van Chu T, Fröhlich A, Steinhauser G, et al. Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat Immunol. 2011;12:151-159.
Gouon-Evans V, Pollard JW. Eotaxin is required for eosinophil homing into the stroma of the pubertal and cycling uterus. Endocrinology. 2001;142:4515-4521.
Simon SCS, Utikal J, Umansky V. Opposing roles of eosinophils in cancer. Cancer immunol immunother. 2019;68:823-833.
Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012;125:5591-5596.
Varricchi G, Galdiero MR, Loffredo S, et al. Eosinophils: The unsung heroes in cancer? Oncoimmunology. 2018;7:e1393134.
Reichman H, Itan M, Rozenberg P, et al. Activated eosinophils exert antitumorigenic activities in colorectal cancer. Cancer Immunol Res. 2019;7:388-400.
Wu D, Molofsky AB, Liang H-E, et al. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science. 2011;332:243-247.
Mahlakõiv T, Flamar A-L, Johnston LK, et al. Stromal cells maintain immune cell homeostasis in adipose tissue via production of interleukin-33. Sci Immunol. 2019;4(35):eaax0416
Simon H-U, Yousefi S, Germic N, et al. The Cellular Functions of Eosinophils: Collegium Internationale Allergologicum (CIA) Update 2020. Int Arch Allergy Immunol. 2020;181:11-23.
Nguyen KD, Qiu Y, Cui X, et al. Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis. Nature. 2011;480:104-108.
Bolus WR, Peterson KR, Hubler MJ, Kennedy AJ, Gruen ML, Hasty AH. Elevating adipose eosinophils in obese mice to physiologically normal levels does not rescue metabolic impairments. Mol Metab. 2018;8:86-95.
Voehringer D, van Rooijen N, Locksley RM. Eosinophils develop in distinct stages and are recruited to peripheral sites by alternatively activated macrophages. J Leukoc Biol. 2007;81:1434-1444.
Ohnmacht C, Pullner A, van Rooijen N, Voehringer D. Analysis of eosinophil turnover in vivo reveals their active recruitment to and prolonged survival in the peritoneal cavity. J Immunol. 1950;2007(179):4766-4774.
Schwartz C, Willebrand R, Huber S, et al. Eosinophil-specific deletion of IκBα in mice reveals a critical role of NF-κB-induced Bcl-xL for inhibition of apoptosis. Blood. 2015;125:3896-3904.
Willebrand R, Voehringer D. IL-33-Induced cytokine secretion and survival of mouse eosinophils is promoted by autocrine GM-CSF. PLoS One. 2016;11:e0163751.
Elishmereni M, Alenius HT, Bradding P, et al. Physical interactions between mast cells and eosinophils. A novel mechanism enhancing eosinophil survival in vitro. Allergy. 2011;66:376-385.
Elishmereni M, Bachelet I, Nissim Ben-Efraim AH, Mankuta D, Levi-Schaffer F. Interacting mast cells and eosinophils acquire an enhanced activation state in vitro. Allergy. 2013;68:171-179.
Gangwar RS, Landolina N, Arpinati L, Levi-Schaffer F. Mast cell and eosinophil surface receptors as targets for anti-allergic therapy. Pharmacol Ther. 2017;170:37-63.
Rocha-de-Souza CM, Berent-Maoz B, Mankuta D, Moses AE, Levi-Schaffer F. Human mast cell activation by Staphylococcus aureus. Interleukin-8 and tumor necrosis factor alpha release and the role of Toll-like receptor 2 and CD48 molecules. Infect Immun. 2008;76:4489-4497.
Gangwar RS, Levi-Schaffer F. sCD48 is anti-inflammatory in Staphylococcus aureus enterotoxin B-induced eosinophilic inflammation. Allergy. 2016;71:829-839.
O'Sullivan JA, Wei Y, Carroll DJ, et al. Frontline Science. Characterization of a novel mouse strain expressing human Siglec-8 only on eosinophils. J Leukoc Biol. 2018;104:11-19.
Soragni A, Yousefi S, Stoeckle C, et al. Toxicity of eosinophil MBP is repressed by intracellular crystallization and promoted by extracellular aggregation. Mol Cell. 2015;57:1011-1021.
Yousefi S, Gold JA, Andina N, et al. Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. Nat Med. 2008;14:949-953.
Morshed M, Yousefi S, Stöckle C, Simon H-U, Simon D. Thymic stromal lymphopoietin stimulates the formation of eosinophil extracellular traps. Allergy. 2012;67:1127-1137.
Ueki S, Melo RCN, Ghiran I, Spencer LA, Dvorak AM, Weller PF. Eosinophil extracellular DNA trap cell death mediates lytic release of free secretion-competent eosinophil granules in humans. Blood. 2013;121:2074-2083.
Dworski R, Simon H-U, Hoskins A, Yousefi S. Eosinophil and neutrophil extracellular DNA traps in human allergic asthmatic airways. J Allergy Clin Immunol. 2011;127:1260-1266.
Simon D, Hoesli S, Roth N, Staedler S, Yousefi S, Simon H-U. Eosinophil extracellular DNA traps in skin diseases. J Allergy Clin Immunol. 2011;127:194-199.
Simon D, Radonjic-Hösli S, Straumann A, Yousefi S, Simon H-U. Active eosinophilic esophagitis is characterized by epithelial barrier defects and eosinophil extracellular trap formation. Allergy. 2015;70:443-452.
Gevaert E, Zhang N, Krysko O, et al. Extracellular eosinophilic traps in association with Staphylococcus aureus at the site of epithelial barrier defects in patients with severe airway inflammation. J Allergy Clin Immunol. 2017;139:1849-1860.e6.
Radonjic-Hoesli S, Wang X, de Graauw E, et al. Adhesion-induced eosinophil cytolysis requires the receptor-interacting protein kinase 3 (RIPK3)-mixed lineage kinase-like (MLKL) signaling pathway, which is counterregulated by autophagy. J Allergy Clin Immunol. 2017;140:1632-1642.
Williams KW, Ware J, Abiodun A, Holland-Thomas NC, Khoury P, Klion AD. Hypereosinophilia in children and adults. A retrospective comparison. J Allergy and Clin Immunol Pract. 2016;4:941-947.e1.
Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndrome. A multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009;124:1319-1325.e3.
Gleich GJ. The pathology of asthma. With emphasis on the role of the eosinophil. N Engl Reg Allergy Proc. 1986;7:421-424.
Rongioletti F, Cecchi F, Pastorino C, Scaparro M. Successful management of refractory angiolymphoid hyperplasia with eosinophilia with thalidomide. J Eur Acad Dermatol Venereol. 2016;30:527-529.
Plötz S-G, Simon H-U, Darsow U, et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med. 2003;349:2334-2339.
Plötz SG, Hüttig B, Aigner B, et al. Clinical overview of cutaneous features in hypereosinophilic syndrome. Curr Allergy Asthma Rep. 2012;12:85-98.
Leiferman KM, Peters MS. Eosinophil-Related Disease and the Skin. The journal of allergy and clinical immunology. practice. 2018;6:1462-1482.e6.
Werfel T, Allam J-P, Biedermann T, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138:336-349.
Oldhoff JM, Darsow U, Werfel T, et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy. 2005;60:693-696.
Kang EG, Narayana PK, Pouliquen IJ, Lopez MC, Ferreira-Cornwell MC, Getsy JA. Efficacy and safety of mepolizumab administered subcutaneously for moderate to severe atopic dermatitis. Allergy. 2020;75:950-953.
Pollmann R, Schmidt T, Eming R, Hertl MP. A Comprehensive review on pathogenesis, clinical presentation and novel therapeutic approaches. Clin Rev Allergy Immunol. 2018;54:1-25.
Engmann J, Rüdrich U, Behrens G, et al. Increased activity and apoptosis of eosinophils in blister fluids, skin and peripheral blood of patients with bullous pemphigoid. Acta dermato-venereologica. 2017;97:464-471.
de Graauw E, Sitaru C, Horn M, et al. Evidence for a role of eosinophils in blister formation in bullous pemphigoid. Allergy. 2017;72:1105-1113.
Rüdrich U, Gehring M, Papakonstantinou E, et al. Eosinophils are a Major Source of Interleukin-31 in Bullous Pemphigoid. Acta dermato-venereologica. 2018;766-771.
Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008;358:1215-1228.
Izumi K, Bieber K, Ludwig RJ. Current clinical trials in pemphigus and pemphigoid. Front Immunol. 2019;10:978.
Simon D, Borradori L, Simon H-U. Eosinophils as putative therapeutic targets in bullous pemphigoid. Exp Dermatol. 2017;26:1187-1192.
Tomassen P, Vandeplas G, van Zele T, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137:1449-1456.e4.
Wang X, Zhang N, Bo M, et al. Diversity of TH cytokine profiles in patients with chronic rhinosinusitis. A multicenter study in Europe, Asia, and Oceania. J Allergy Clin Immunol. 2016;138:1344-1353.
Stentzel S, Teufelberger A, Nordengrün M, et al. Staphylococcal serine protease-like proteins are pacemakers of allergic airway reactions to Staphylococcus aureus. J Allergy Clin Immunol. 2017;139:492-500.e8.
Teufelberger AR, Nordengrün M, Braun H, et al. The IL-33/ST2 axis is crucial in type 2 airway responses induced by Staphylococcus aureus-derived serine protease-like protein D. J Allergy Clin Immunol. 2018;141:549-559.e7.
Bachert C, Sousa AR, Lund VJ, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab. Randomized trial. J Allergy Clin Immunol. 2017;140:1024-1031.e14.
Bachert C, Zhang N, Hellings PW, Bousquet J. Endotype-driven care pathways in patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2018;141:1543-1551.
Allen J, Wert ME. Eosinophilic pneumonias. J Allergy Clin Immunol Pract. 2018;6:1455-1461.
Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol. 1951;27:277-301.
Wu EY, Hernandez ML, Jennette JC, Falk RJ. Eosinophilic granulomatosis with polyangiitis clinical pathology conference and review. J Allergy Clin Immunol Pract. 2018;6:1496-1504.
Ortega H, Katz L, Gunsoy N, Keene O, Yancey S. Blood eosinophil counts predict treatment response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2015;136:825-826.
FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA). A randomised, double-blind, placebo-controlled phase 3 trial, (vol. 388). Lancet (London, England): 2016:2128-2141.
Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198-1207.
Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189-1197.
Nair P, Wenzel S, Rabe KF, et al. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med. 2017;376:2448-2458.
Kim S, Marigowda G, Oren E, Israel E, Wechsler ME. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol. 2010;125:1336-1343.
Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or Placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376:1921-1932.
Straumann AE. Eosinophilic esophagitis: emerging therapies and future perspectives. Gastroenterol Clin North Am. 2014;43:385-394.
Dellon ES, Hirano I. Epidemiology and Natural History of Eosinophilic Esophagitis. Gastroenterology. 2018;154:319-332:e3.
O'Shea KM, Aceves SS, Dellon ES, et al. Pathophysiology of eosinophilic esophagitis. Gastroenterology. 2018;154:333-345.
Shaheen NJ, Mukkada V, Eichinger CS, Schofield H, Todorova L, Falk GW. Natural history of eosinophilic esophagitis: a systematic review of epidemiology and disease course. Dis Esophagus. 2018;31. https://doi.org/10.1093/dote/doy015. (ahead of print)
Hill DA, Dudley JW, Spergel JM. The prevalence of eosinophilic esophagitis in pediatric patients with IgE-mediated food allergy. J Allergy Clin Immunol Pract. 2017;5:369-375.
Ruffner MA, Spergel JM. Eosinophilic esophagitis in children. Curr Allergy Asthma Rep. 2017;17:54.
Molina-Infante J, Bredenoord AJ, Cheng E, et al. Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. Gut. 2016;65:524-531.
Lucendo AJ, Molina-Infante J, Arias Á, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European gastroenterology J. 2017;5:335-358.
Gleich GJ. Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol. 2000;105:651-663.
Hogan SP, Rosenberg HF, Moqbel R, Phipps S, Foster PS, Lacy P, et al. Eosinophils Biological properties and role in health and disease. Clin Exp Allergy. 2008;38:709-50.
Tefferi A, Patnaik MM, Pardanani AE. Secondary, clonal and idiopathic. Br J Haematol. 2006;133:468-492.
Simon D, Simon H-U. Eosinophilic disorders. J Allergy Clin Immunol. 2007;119:1291-300; quiz 1301-2.
Valent P, Klion AD, Horny H-P, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012;130:607-612.e9.
Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360:973-984.
Wagener AH, de Nijs SB, Lutter R, et al. External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax. 2015;70:115-120.
Siddiqui SH, Guasconi A, Vestbo J, et al. Blood eosinophils. A biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192:523-525.
Brightling CE, Bleecker ER, Panettieri RA, et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia. A randomised, double-blind, placebo-controlled, phase 2a study. The Lancet. Respir Med. 2014;2:891-901.
Khoury P, Bochner BS. Consultation for elevated blood eosinophils. Clinical presentations, high value diagnostic tests, and treatment options. J Allergy Clin Immunol Pract. 2018;6:1446-1453.
Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201-1214.
Valent P. Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders. Blood Rev. 2009;23:157-165.
Radonjic-Hoesli S, Valent P, Klion AD, Wechsler ME, Simon H-U. Novel targeted therapies for eosinophil-associated diseases and allergy. Annu Rev Pharmacol Toxicol. 2015;55:633-656.
Fassnacht F, Roumier M, Fouret P, et al. Successful Heart Transplantation for unreversible endomyocardial fibrosis related to FIP1L1-PDGFRA chronic eosinophilic leukemia. Transplantation. 2015;99:e176-e177.
Kuang FL, Legrand F, Makiya M, et al. Benralizumab for PDGFRA-negative Hypereosinophilic syndrome. N Engl J Med. 2019;380:1336-1346.
Krug N, Hohlfeld JM, Kirsten A-M, et al. Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. N Engl J Med. 2015;372:1987-1995.
Greulich T, Hohlfeld JM, Neuser P, et al. A GATA3-specific DNAzyme attenuates sputum eosinophilia in eosinophilic COPD patients. A feasibility randomized clinical trial. Respir Res. 2018;19(1):55.
Rosenberg HF, Dyer KD, Foster PSE. Changing perspectives in health and disease. Nat Rev Immunol. 2013;13:9-22.
Klion ADE. A pragmatic approach to diagnosis and treatment. Hematology Am Soc Hematol Educ Program. 2015;2015;92-97.